Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03241823|
Recruitment Status : Unknown
Verified August 2017 by Ibrahim Taha, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : August 8, 2017
Last Update Posted : August 8, 2017
|Condition or disease||Intervention/treatment|
|Hepatitis C Liver Cirrhosis||Diagnostic Test: Abdominal ultrasound . Diagnostic Test: Model for End-Stage Liver Disease Diagnostic Test: Fibro Scan. Diagnostic Test: Child-Turcotte-Pugh score.|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Assessment of Hepatic Fibrosis, Hemodynamics, and Disease Severity of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.|
|Estimated Study Start Date :||December 1, 2017|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||March 2019|
Patients with hepatitis c virus related liver cirrhosis
Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan "F3 and F4, Child score "A and B", of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin).
Diagnostic Test: Abdominal ultrasound .
Abdominal ultrasound for each patient before and after treatment.
Diagnostic Test: Model for End-Stage Liver Disease
Model for End-Stage Liver Disease before and after treatment.
Diagnostic Test: Fibro Scan.
Liver stiffness by Fibro scan before and after treatment.
Diagnostic Test: Child-Turcotte-Pugh score.
Child-Turcotte-Pugh score before and after treatment
- Changes in liver fibrosis [ Time Frame: 1 year. ]Using non-invasive measures "Fibroscan"
- Changes occurring in liver haemodynamics [ Time Frame: 1 year. ]Using Doppler ultrasound.
- Changes in severity of liver disease [ Time Frame: 1 year ]Using Child-Pugh score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03241823
|Contact: Sherif Kamel, MDfirstname.lastname@example.org|
|Contact: Sahar Hassany, MDemail@example.com|
|Assuit Unit of Treatment of Viral Hepatitis.||Not yet recruiting|
|Assuit, Egypt, 71111|
|Contact: Waleed Hassan, MD 00201020066191 firstname.lastname@example.org|
|Principal Investigator:||Ibrahim Taha, MSc||Assiut University|